Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Review

Multicenter Study

Clinical Trial, Phase III

Clinical Trial, Phase II

Clinical Trial

Research Support, N.I.H., Extramural

Clinical Trial, Phase I

Meta-Analysis

Letter

Clinical Trial, Phase IV

Observational Study

Publication Year

From

Quick links

Individual year

2023

2022

2021

2019

2018

2017

2015

2014

2013

2012

2011

2010

2009

2008

2007

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Maraviroc""[mesh_terms]

31 Results

Searching titles within these results

Immunotherapies in HIV-1 infection.

Sarah L Pett

Current opinion in HIV and AIDS 2009;4(3):188-93

Full Text

Abstract

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby

PloS one 2019;13(12):e0204099

Free Full Text

Abstract

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.

M Surdo, C Alteri, M C Puertas, P Saccomandi, L Parrotta, L Swenson, D Chapman, G Costa, A Artese, E Balestra, S Aquaro, S Alcaro, M Lewis, B Clotet, R Harrigan, H Valdez, V Svicher, C F Perno, J Martinez-Picado, F Ceccherini-Silberstein

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2015;21(1):103.e1-6

Free Full Text

Abstract

Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.

Georg Martin Haag, Christoph Springfeld, Barbara Grün, Leonidas Apostolidis, Stefanie Zschäbitz, Mareike Dietrich, Anne-Katrin Berger, Tim Frederik Weber, Inka Zoernig, Marina Schaaf, Lisa Waberer, Daniel Wilhelm Müller, Salah-Eddin Al-Batran, Niels Halama, Dirk Jaeger

European journal of cancer (Oxford, England : 1990) 2022;167():112-122

Full Text

Abstract

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.

Fedora Grande, Maria Antonietta Occhiuzzi, Bruno Rizzuti, Giuseppina Ioele, Michele De Luca, Paola Tucci, Valentina Svicher, Stefano Aquaro, Antonio Garofalo

Molecules (Basel, Switzerland) 2019;24(3):550

Free Full Text

Abstract

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.

Claire Pressiat, Déborah Hirt, Jean-Marc Treluyer, Yi Zheng, Philippe Morlat, Alice Naqvi, Laurent Tran, Jean-Paul Viard, Véronique Avettand-Fenoel, Christine Rouzioux, Laurence Meyer, Antoine Cheret

The Journal of antimicrobial chemotherapy 2019;73(4):1020-1024

Full Text

Abstract

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Mackenzie L Cottrell, Heather M A Prince, Andrew Allmon, Katie R Mollan, Michael G Hudgens, Craig Sykes, Nicole White, Stephanie Malone, Evan S Dellon, Ryan D Madanick, Nicholas J Shaheen, Kristine B Patterson, Angela D M Kashuba

Journal of acquired immune deficiency syndromes (1999) 2017;72(5):498-506

Free Full Text

Abstract

Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals.

Borja Mora-Peris, George Bouliotis, Kulasegaram Ranjababu, Amanda Clarke, Frank A Post, Mark Nelson, Laura Burgess, Juan Tiraboschi, Saye Khoo, Steve Taylor, Deborah Ashby, Alan Winston

AIDS (London, England) 2019;32(8):1007-1015

Free Full Text

Abstract

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

Lucy Garvey, Mark Nelson, Ngaire Latch, Otto W Erlwein, Joanna M Allsop, Ann Mitchell, Steve Kaye, Victoria Watson, David Back, Simon D Taylor-Robinson, Alan Winston

The Journal of antimicrobial chemotherapy 2012;67(1):206-12

Full Text

Abstract

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.

Nontokozo D Matume, Denis M Tebit, Pascal O Bessong

AIDS research and therapy 2021;17(1):5

Free Full Text

Abstract

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.

J M Emmelkamp, J K Rockstroh

European journal of medical research 2007;12(9):409-17

Full Text

Abstract

Pharmacokinetics, the Immunological Impact, and the Effect on HIV Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.

Lorna Leal, Alberto C Guardo, Luis M Bedoya, Cristina Rodríguez de Miguel, Núria Climent, Cristina Rovira, Manuela Beltrán, Josep Llach, Jose Alcamí, Angela D M Kashuba, Jose M Gatell, Montserrat Plana, Felipe García

AIDS research and human retroviruses 2023;39(5):211-221

Free Full Text

Abstract

Targeting CCR5 for anti-HIV research.

W-G Gu, X-Q Chen

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2015;33(11):1881-7

Full Text

Abstract

Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial.

A MacInnes, A Lazzarin, G Di Perri, J G Sierra-Madero, J Aberg, J Heera, N Rajicic, J Goodrich, H Mayer, H Valdez

HIV clinical trials 2011;12(1):24-36

Full Text

Abstract

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.

Pierre Pradat, Jacques Durant, Corinne Brochier, Mary-Anne Trabaud, Jacqueline Cottalorda-Dufayard, Jacques Izopet, François Raffi, Frédéric Lucht, Marie-Claude Gagnieu, Caroline Gatey, Christine Jacomet, Matteo Vassallo, Pierre Dellamonica, Laurent Cotte

The Journal of antimicrobial chemotherapy 2017;71(11):3235-3241

Full Text

Abstract

Results: 1 – 15 / 31

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Maraviroc""[mesh_terms]

Immunotherapies in HIV-1 infection.

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.

Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals.

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.

Pharmacokinetics, the Immunological Impact, and the Effect on HIV Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.

Targeting CCR5 for anti-HIV research.

Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial.

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.

Results for
""Maraviroc""[mesh_terms]